

David M Weinstock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6570337/publications.pdf>

Version: 2024-02-01

171
papers

12,693
citations

28736

57
h-index

31191

106
g-index

176
all docs

176
docs citations

176
times ranked

22505
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. <i>Cancer Discovery</i> , 2022, 12, 522-541.	7.7	44
2	Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 154-169.	2.6	8
3	Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1. <i>Blood</i> , 2022, 139, 2024-2037.	0.6	9
4	A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia. <i>Genes and Development</i> , 2022, 36, 368-389.	2.7	14
5	The molecular ontogeny of follicular lymphoma: gene mutations succeeding the <i>BCL2</i> translocation define common precursor cells. <i>British Journal of Haematology</i> , 2022, 196, 1381-1387.	1.2	5
6	RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia. <i>Oncogene</i> , 2021, 40, 746-762.	2.6	5
7	Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features. <i>Blood Advances</i> , 2021, 5, 649-661.	2.5	26
8	Low-cost transcriptional diagnostic to accurately categorize lymphomas in low- and middle-income countries. <i>Blood Advances</i> , 2021, 5, 2447-2455.	2.5	13
9	Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. <i>IScience</i> , 2021, 24, 102651.	1.9	4
10	Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway. <i>Blood</i> , 2021, 138, 2435-2440.	0.6	10
11	A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. <i>Blood</i> , 2021, 138, 2828-2837.	0.6	65
12	Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 616-616.	0.6	1
13	Identification of a Conserved Intracellular Loop (CIL) Structure That Scaffolds PIP3 to Amplify Oncogenic Signaling during Malignant B-Cell Transformation. <i>Blood</i> , 2021, 138, 868-868.	0.6	0
14	Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608. <i>Blood</i> , 2021, 138, 2425-2425.	0.6	0
15	Maturity State and MCL-1 Dependence Predetermines Response to NOTCH1 Inhibition in T-ALL. <i>Blood</i> , 2021, 138, 3484-3484.	0.6	0
16	Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid Malignancies. <i>Blood</i> , 2021, 138, 355-355.	0.6	0
17	AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells. <i>Clinical Cancer Research</i> , 2020, 26, 922-934.	3.2	165
18	46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020, 2, ii9-ii9.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Polymerase $\hat{\Gamma}$ promotes chromosomal rearrangements and imprecise double-strand break repair. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27566-27577.	3.3	15
20	Signalling input from divergent pathways subverts B cell transformation. Nature, 2020, 583, 845-851.	13.7	37
21	DT2216 is a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. Journal of Hematology and Oncology, 2020, 13, 95.	6.9	64
22	Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell, 2020, 38, 872-890.e6.	7.7	80
23	On Grieving for the Out-of-Practice. New England Journal of Medicine, 2020, 383, 1809-1811.	13.9	2
24	Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma. Cell Reports, 2020, 31, 107522.	2.9	50
25	Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions. Blood, 2020, 135, 1467-1471.	0.6	24
26	A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. Cancers, 2020, 12, 1603.	1.7	11
27	Breaking Down the Barriers to Define and Treat NK/T Cell Lymphoma. Cancer Cell, 2020, 37, 263-265.	7.7	2
28	Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma. Blood Advances, 2020, 4, 1265-1269.	2.5	5
29	TMOD-03. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. Neuro-Oncology, 2020, 22, ii228-ii228.	0.6	0
30	Targeted inhibition of CD47-SIRP $\hat{\alpha}$ requires Fc-Fc $\hat{\gamma}$ 3R interactions to maximize activity in T-cell lymphomas. Blood, 2019, 134, 1430-1440.	0.6	45
31	Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. PLoS ONE, 2019, 14, e0221288.	1.1	16
32	Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature, 2019, 569, 503-508.	13.7	2,149
33	Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. Cancer Discovery, 2019, 9, 944-961.	7.7	36
34	TFH lymphomas: the times they aza-changin $\hat{\alpha}$ ™?. Blood, 2019, 134, 1364-1365.	0.6	1
35	Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models. Scientific Reports, 2019, 9, 17161.	1.6	25
36	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Clinical Cancer Research, 2019, 25, 7046-7057.	3.2	56

#	ARTICLE	IF	CITATIONS
37	Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. <i>Blood</i> , 2019, 133, 952-961.	0.6	117
38	Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. <i>Blood</i> , 2019, 133, 566-575.	0.6	44
39	DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. <i>Journal of Clinical Investigation</i> , 2019, 129, 5005-5019.	3.9	59
40	Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4019-4019.	0.6	20
41	A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults. <i>Blood</i> , 2019, 134, 3879-3879.	0.6	5
42	Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling. <i>Blood</i> , 2019, 134, 393-393.	0.6	0
43	DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia. <i>Blood</i> , 2019, 134, 303-303.	0.6	3
44	Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies. <i>Blood</i> , 2019, 134, 295-295.	0.6	0
45	Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2551-2551.	0.6	0
46	Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL. <i>Blood</i> , 2019, 134, 3948-3948.	0.6	0
47	A Clinically-Indolent Variant of Extranodal NK/T Cell Lymphoma with Unique Immunophenotypic Profile and Superior Outcome. <i>Blood</i> , 2019, 134, 5278-5278.	0.6	0
48	An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. <i>Leukemia</i> , 2018, 32, 1970-1983.	3.3	282
49	Rapid identification of <i>BCR/ABL</i> like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time polymerase chain reaction: clinical, prognostic and therapeutic implications. <i>British Journal of Haematology</i> , 2018, 181, 642-652.	1.2	46
50	Targeting minimal residual disease: a path to cure?. <i>Nature Reviews Cancer</i> , 2018, 18, 255-263.	12.8	106
51	Clinicogenetic risk modeling in ATL. <i>Blood</i> , 2018, 131, 159-160.	0.6	5
52	Activity of the PI3K-Î³ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. <i>Blood</i> , 2018, 131, 888-898.	0.6	224
53	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 514-520.	2.0	31
54	Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. <i>Oncotarget</i> , 2018, 9, 8027-8041.	0.8	42

#	ARTICLE	IF	CITATIONS
55	Parp3 promotes long-range end joining in murine cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10076-10081.	3.3	11
56	Challenges and implications of genomics for T-cell lymphomas. Hematology American Society of Hematology Education Program, 2018, 2018, 63-68.	0.9	11
57	RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. Blood, 2018, 132, 935-947.	0.6	87
58	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nature Communications, 2018, 9, 2024.	5.8	80
59	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. Journal of Investigative Dermatology, 2018, 138, 2365-2376.	0.3	59
60	Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. PLoS ONE, 2018, 13, e0199708.	1.1	4
61	Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood, 2018, 132, 1495-1506.	0.6	100
62	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. Blood, 2018, 132, 1695-1702.	0.6	49
63	Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies. Blood, 2018, 132, 263-263.	0.6	0
64	Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations. EMBO Molecular Medicine, 2017, 9, 498-507.	3.3	86
65	Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2017, 23, 1012-1024.	3.2	88
66	PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nature Communications, 2017, 8, 15110.	5.8	32
67	The promise of organ and tissue preservation to transform medicine. Nature Biotechnology, 2017, 35, 530-542.	9.4	371
68	Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 6581-6586.	3.3	32
69	It Takes a Village to Unmask HSTL. Cancer Discovery, 2017, 7, 352-353.	7.7	1
70	Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia. British Journal of Haematology, 2017, 177, 271-282.	1.2	28
71	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Research, 2017, 77, e62-e66.	0.4	92
72	Inhibition of USP10 induces degradation of oncogenic FLT3. Nature Chemical Biology, 2017, 13, 1207-1215.	3.9	89

#	ARTICLE	IF	CITATIONS
73	A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. Cell Reports, 2017, 21, 784-797.	2.9	65
74	The next best thing. Nature, 2017, 549, 39-41.	13.7	5
75	The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. Blood, 2017, 130, 1491-1498.	0.6	29
76	Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nature Genetics, 2017, 49, 10-16.	9.4	307
77	Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice. Blood Advances, 2017, 1, 2361-2374.	2.5	11
78	Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget, 2017, 8, 52026-52044.	0.8	19
79	HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. Blood, 2016, 128, 2517-2526.	0.6	37
80	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	7.7	227
81	Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood, 2016, 128, 1093-1100.	0.6	126
82	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood, 2016, 128, 1112-1120.	0.6	177
83	High-throughput measurement of single-cell growth rates using serial microfluidic mass sensor arrays. Nature Biotechnology, 2016, 34, 1052-1059.	9.4	201
84	Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nature Biotechnology, 2016, 34, 1161-1167.	9.4	91
85	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood, 2016, 127, 2203-2213.	0.6	68
86	Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Reports, 2016, 14, 429-439.	2.9	118
87	Buying cures versus renting health: Financing health care with consumer loans. Science Translational Medicine, 2016, 8, 327ps6.	5.8	31
88	mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL. Blood, 2016, 128, 2763-2763.	0.6	5
89	A Functional Characterization of BCL2-Family Members Identifies BH3 Mimetics As Potential Therapeutics in T-Cell Lymphomas. Blood, 2016, 128, 292-292.	0.6	2
90	T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development. Blood, 2016, 128, 3015-3015.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Notch-Regulated Enhancers in B-Cell Lymphoma Activate MYC and Potentiate B-Cell Receptor Signaling. <i>Blood</i> , 2016, 128, 457-457.	0.6	2
92	Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 830-830.	0.6	3
93	Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. <i>Oncotarget</i> , 2016, 7, 51494-51502.	0.8	35
94	Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS-Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109. <i>Blood</i> , 2016, 128, 2749-2749.	0.6	0
95	FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 1681-1681.	0.6	0
96	Exploring RhoA G17V-Mediated T-Cell Dysfunction. <i>Blood</i> , 2016, 128, 1567-1567.	0.6	7
97	Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia. <i>Blood</i> , 2016, 128, 524-524.	0.6	0
98	Anti-Leukemic Activity of the TYK2 Selective Inhibitor Ndi-031301 in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 1596-1596.	0.6	0
99	A roadmap for discovery and translation in lymphoma. <i>Blood</i> , 2015, 125, 2175-2177.	0.6	18
100	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. <i>Lancet Oncology</i> , The, 2015, 16, 1111-1122.	5.1	483
101	Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 28, 29-41.	7.7	95
102	Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. <i>Science Advances</i> , 2015, 1, e1500221.	4.7	73
103	Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. <i>Nature Medicine</i> , 2015, 21, 71-75.	15.2	106
104	Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 2529-2529.	0.6	3
105	Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma. <i>Blood</i> , 2015, 126, 3252-3252.	0.6	2
106	A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 333-333.	0.6	7
107	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 522-522.	0.6	3
108	Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 571-571.	0.6	1

#	ARTICLE	IF	CITATIONS
109	The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts. <i>Blood</i> , 2015, 126, 797-797.	0.6	9
110	Navigating Future Challenges in Lymphoma: A Map for the Road Ahead. , 2015, 12, .		0
111	Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets. <i>Blood</i> , 2015, 126, 2655-2655.	0.6	0
112	B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development. <i>Blood</i> , 2015, 126, 4001-4001.	0.6	0
113	Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture Molecular and Biologic Heterogeneity and Inform Therapy. <i>Blood</i> , 2015, 126, 817-817.	0.6	5
114	Ubiquitin-specific Peptidase 20 Regulates Rad17 Stability, Checkpoint Kinase 1 Phosphorylation and DNA Repair by Homologous Recombination. <i>Journal of Biological Chemistry</i> , 2014, 289, 22739-22748.	1.6	28
115	Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. <i>Nature Genetics</i> , 2014, 46, 618-623.	9.4	117
116	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2014, 123, 1293-1296.	0.6	345
117	PARP1 is required for chromosomal translocations. <i>Blood</i> , 2013, 121, 4359-4365.	0.6	67
118	Inactivation of <i>Uaf1</i> Causes Defective Homologous Recombination and Early Embryonic Lethality in Mice. <i>Molecular and Cellular Biology</i> , 2013, 33, 4360-4370.	1.1	38
119	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. <i>PLoS ONE</i> , 2013, 8, e67306.	1.1	98
120	Efficacy and Mechanisms Of The mTOR Inhibitor AZD2014 Combined With L-Asparaginase Or JAK2 Inhibitor TG101348 In ALL. <i>Blood</i> , 2013, 122, 1282-1282.	0.6	2
121	Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance. <i>Blood</i> , 2013, 122, 741-741.	0.6	18
122	HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase. <i>Blood</i> , 2013, 122, 2528-2528.	0.6	0
123	Integrated Analysis Of CRLF2 Signaling In Acute Lymphoblastic Leukemia Identifies Polo-Like Kinase 1 As a Therapeutic Target. <i>Blood</i> , 2013, 122, 2667-2667.	0.6	0
124	JAK2 L884P Mutation Confers Resistance To The Type II JAK2 Inhibitor NVP-BBT594 When Co-Occurring With JAK2 R683G But Not JAK2 V617F. <i>Blood</i> , 2013, 122, 1429-1429.	0.6	0
125	Targeting Oncogenic Interleukin-7 Receptor Signaling With N-Acetylcysteine In T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 2535-2535.	0.6	0
126	The Beta-Subunit Of Heterotrimeric G Proteins Harbors Gain-Of-Function Mutations In Multiple Hematologic Malignancies. <i>Blood</i> , 2013, 122, 2510-2510.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation. <i>Cancer Discovery</i> , 2012, 2, 47-55.	7.7	89
128	Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. <i>Journal of Experimental Medicine</i> , 2012, 209, 259-273.	4.2	146
129	Medical Planning and Response for a Nuclear Detonation: A Practical Guide. <i>Biosecurity and Bioterrorism</i> , 2012, 10, 346-371.	1.2	29
130	BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 2843-2852.	0.6	329
131	BCL2 Suppresses PARP1 Function and Nonapoptotic Cell Death. <i>Cancer Research</i> , 2012, 72, 4193-4203.	0.4	49
132	Next-Generation cDNA Screening for Oncogene and Resistance Phenotypes. <i>PLoS ONE</i> , 2012, 7, e49201.	1.1	9
133	Planning and Response to Radiation Exposures. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1262-1263.	2.0	1
134	miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors. <i>Molecular Cell</i> , 2011, 41, 210-220.	4.5	409
135	Repair at Single Targeted DNA Double-Strand Breaks in Pluripotent and Differentiated Human Cells. <i>PLoS ONE</i> , 2011, 6, e20514.	1.1	38
136	Radiation Injury After a Nuclear Detonation: Medical Consequences and the Need for Scarce Resources Allocation. <i>Disaster Medicine and Public Health Preparedness</i> , 2011, 5, S32-S44.	0.7	183
137	Allocation of Scarce Resources After a Nuclear Detonation: Setting the Context. <i>Disaster Medicine and Public Health Preparedness</i> , 2011, 5, S20-S31.	0.7	63
138	First Global Consensus for Evidence-Based Management of the Hematopoietic Syndrome Resulting From Exposure to Ionizing Radiation. <i>Disaster Medicine and Public Health Preparedness</i> , 2011, 5, 202-212.	0.7	91
139	Literature Review and Global Consensus on Management of Acute Radiation Syndrome Affecting Nonhematopoietic Organ Systems. <i>Disaster Medicine and Public Health Preparedness</i> , 2011, 5, 183-201.	0.7	78
140	Radiation Injury Treatment Network (RITN): Healthcare professionals preparing for a mass casualty radiological or nuclear incident. <i>International Journal of Radiation Biology</i> , 2011, 87, 748-753.	1.0	16
141	Molecular Ontogeny of Donor-Derived Lymphomas Occurring After Transplantation. <i>Blood</i> , 2011, 118, 3671-3671.	0.6	0
142	Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition. <i>Blood</i> , 2011, 118, 62-62.	0.6	5
143	HSP90 Inhibition Targets JAK2 and Is Highly Effective in CRLF2-Rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 576-576.	0.6	2
144	MEDICAL MANAGEMENT OF RADIATION VICTIMS IN THE UNITED STATES. <i>Health Physics</i> , 2010, 98, 833-837.	0.3	6

#	ARTICLE	IF	CITATIONS
145	Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 252-257.	3.3	314
146	The p400 ATPase regulates nucleosome stability and chromatin ubiquitination during DNA repair. Journal of Cell Biology, 2010, 191, 31-43.	2.3	166
147	Epstein-Barr Virus, Lymphoma Risk and the Potential Role of HIV Infection in IBD Patients Undergoing Immunosuppression. Digestive Diseases, 2010, 28, 519-524.	0.8	11
148	Assessing Surge Capacity for Radiation Victims with Marrow Toxicity. Biology of Blood and Marrow Transplantation, 2010, 16, 1436-1441.	2.0	9
149	Chromosomal translocations induced at specified loci in human stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10620-10625.	3.3	184
150	Stem Cells, Multiorgan Failure in Radiation Emergency Medical Preparedness: A U.S./European Consultation Workshop. Stem Cells, 2009, 27, 1205-1211.	1.4	47
151	Inactivation of Murine Usp1 Results in Genomic Instability and a Fanconi Anemia Phenotype. Developmental Cell, 2009, 16, 314-320.	3.1	217
152	The Evolution of Influenza Resistance and Treatment. JAMA - Journal of the American Medical Association, 2009, 301, 1066.	3.8	86
153	A PP4-Phosphatase Complex Dephosphorylates γ -H2AX Generated during DNA Replication. Molecular Cell, 2008, 31, 33-46.	4.5	218
154	Induction of Chromosomal Translocations in Mouse and Human Cells Using Site-Specific Endonucleases. Journal of the National Cancer Institute Monographs, 2008, 2008, 20-24.	0.9	26
155	Radiologic and nuclear events: contingency planning for hematologists/oncologists. Blood, 2008, 111, 5440-5445.	0.6	65
156	Response: Radiologic and nuclear events. Blood, 2008, 111, 5758-5759.	0.6	7
157	Colonization, Bloodstream Infection, and Mortality Caused by Vancomycin-Resistant Enterococcus Early after Allogeneic Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2007, 13, 615-621.	2.0	189
158	Formation of NHEJ-derived reciprocal chromosomal translocations does not require Ku70. Nature Cell Biology, 2007, 9, 978-981.	4.6	130
159	BCR-ABL Induces Error-Prone Single Strand Annealing in Transformed Cells.. Blood, 2007, 110, 2937-2937.	0.6	0
160	Modeling oncogenic translocations: Distinct roles for double-strand break repair pathways in translocation formation in mammalian cells. DNA Repair, 2006, 5, 1065-1074.	1.3	150
161	A model of oncogenic rearrangements: differences between chromosomal translocation mechanisms and simple double-strand break repair. Blood, 2006, 107, 777-780.	0.6	89
162	Progression of Pneumocystis jiroveci Pneumonia in Patients Receiving Echinocandin Therapy. Clinical Infectious Diseases, 2006, 43, e92-e94.	2.9	48

#	ARTICLE	IF	CITATIONS
163	Alternative Pathways for the Repair of RAG-Induced DNA Breaks. <i>Molecular and Cellular Biology</i> , 2006, 26, 131-139.	1.1	48
164	Assaying Double-Strand Break Repair Pathway Choice in Mammalian Cells Using a Targeted Endonuclease or the RAG Recombinase. <i>Methods in Enzymology</i> , 2006, 409, 524-540.	0.4	141
165	Adamantane Resistance in Influenza A. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 934-936.	3.8	16
166	PCR Screening for Epstein-Barr Virus-Related Lymphoproliferative Disease (EBV-LPD) among Allogeneic Stem Cell Transplant (AlloSCT) Recipients: The Importance of T Cell Depletion.. <i>Blood</i> , 2005, 106, 3234-3234.	0.6	7
167	Postexposure Prophylaxis Against Varicella-Zoster Virus Infection Among Recipients of Hematopoietic Stem Cell Transplant: Unresolved Issues. <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 603-608.	1.0	47
168	Prolonged Shedding of Multidrug-Resistant Influenza A Virus in an Immunocompromised Patient. <i>New England Journal of Medicine</i> , 2003, 348, 867-868.	13.9	185
169	Rhodococcus equi: An Emerging Pathogen. <i>Clinical Infectious Diseases</i> , 2002, 34, 1379-1385.	2.9	248
170	Rotavirus outbreak on a pediatric oncology floor: Possible association with toys. <i>American Journal of Infection Control</i> , 2000, 28, 378-380.	1.1	60
171	Control of Influenza A on a Bone Marrow Transplant Unit. <i>Infection Control and Hospital Epidemiology</i> , 2000, 21, 730-732.	1.0	95